PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79725R0019 for an unrestricted procurement for Bevacizumab Injections, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC).
VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs.
Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product.
Solicitation # 36E79725R0019 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about February 18, 2025, with a tentative closing date of March 04, 2025. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Matthew Poulin. Questions can be e-mailed to Matthew.Poulin@va.gov.
The estimated annual requirements are as follows:
REQUIREMENT DESCRIPTION
ITEM
DESCRIPTION
PACKAGE SIZE (VIAL)
TOTAL ESTIMATED ANNUAL USAGE (VIAL)
1a
BEVACIZUMAB 25MG/ML INJ (Trade Name Avastin)
4ML
23,448
1b
BEVACIZUMAB 25MG/ML INJ (Trade Name Avastin)
16ML
13,841
OR
2a
BEVACIZUMAB-AWWB 25MG/ML INJ (Trade Name Mvasi)
4ML
23,212
2b
BEVACIZUMAB-AWWB 25MG/ML INJ (Trade Name Mvasi)
16ML
4,808
OR
3a
BEVACIZUMAB-MALY 25MG/ML INJ (Trade Name Alymsys)
4ML
23,448
3b
BEVACIZUMAB-MALY 25MG/ML INJ (Trade Name Alymsys)
16ML
13,841
OR
4a
BEVACIZUMAB-ADCD 25MG/ML INJ (Trade Name Vegzelma)
4ML
23,448
4b
BEVACIZUMAB-ADCD 25MG/ML INJ (Trade Name Vegzelma)
16ML
13,841
OR
5a
BEVACIZUMAB-BVZR 25MG/ML INJ (Trade Name Zirabev)
4ML
23,448
5b
BEVACIZUMAB-BVZR 25MG/ML INJ (Trade Name Zirabev)
16ML
13,841